Fundación CIDEA - Buenos Aires

Para la investigación y difusión de las enfermedades alérgicas, respiratorias y otras. Institución afiliada a la Facultad de Medicina de la Universidad de Buenos Aires.

Paraguay 2035, C1121ABE Cdad. Autónoma de Buenos Aires, Argentina

Websitehttps://fundacioncidea.org.ar/

Select an option

I am a doctor

I am a sponsor

Our team

Medical staff

Monica Silvia De Gennaro

Jorge Máspero

Investigadora PrincipalAndrea Rosana Baños

Legal and Administrative staff

QAMaria Ines Antunez

Study Coordinator Julieta Peverini

Open studies

Asthma

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma - INC 54707-208 - Incyte Corporation

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) - Regeneron Pharmaceuticals

Dermatitis

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis - ADorable-1 - Dermira, Inc.

Urticaria

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria - EMBARQ-CSU1 - Celldex Therapeutics

About usOur mission Our team Partners FAQs

Medical newsLatest news Studies Interviews Testimonials

ProductsUEPM Onco UEPM Physicians

LinksDownloads

Fundación CIDEA - Buenos Aires

Para la investigación y difusión de las enfermedades alérgicas, respiratorias y otras. Institución afiliada a la Facultad de Medicina de la Universidad de Buenos Aires.

Fundación CIDEA - Buenos Aires

Paraguay 2035, C1121ABE Cdad. Autónoma de Buenos Aires, Argentina

Websitehttps://fundacioncidea.org.ar/

Select an option

I am a doctor

I am a sponsor

Our team

Medical staff

Monica Silvia De Gennaro

Jorge Máspero

Investigadora PrincipalAndrea Rosana Baños

Legal and Administrative staff

QAMaria Ines Antunez

Study Coordinator Julieta Peverini

Open studies

Asthma

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma - INC 54707-208 - Incyte Corporation

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) - Regeneron Pharmaceuticals

Dermatitis

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis - ADorable-1 - Dermira, Inc.

Urticaria

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria - EMBARQ-CSU1 - Celldex Therapeutics

About usOur mission Our team Partners FAQs

Medical newsLatest news Studies Interviews Testimonials

ProductsUEPM Onco UEPM Physicians

LinksDownloads